{"id":"proflavine-hemisulfate","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or sensitization (topical use)"},{"rate":null,"effect":"Phototoxicity"},{"rate":null,"effect":"Systemic toxicity (if absorbed)"}]},"_chembl":null,"_dailymed":{"setId":"074d2603-ec76-49ca-a0ae-79ce8b90d8ab","title":"PERINEZE TRIPLE DYE (BRILLIANT GREEN, PROFLAVINE HEMISULFATE, GENTIAN VIOLET) SOLUTION [PEACE MEDICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an acridine derivative, proflavine intercalates between DNA base pairs, disrupting replication and transcription. It also generates reactive oxygen species that damage cellular components. Historically used as a topical antiseptic and antimicrobial agent, it has been investigated for anticancer properties due to its ability to inhibit cell proliferation and induce oxidative stress in tumor cells.","oneSentence":"Proflavine hemisulfate is an acridine dye that intercalates into DNA and generates reactive oxygen species, causing direct antimicrobial and antiproliferative effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:04:23.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Topical antiseptic and antimicrobial agent (historical use)"},{"name":"Investigational anticancer agent (limited clinical development)"}]},"trialDetails":[{"nctId":"NCT06435286","phase":"PHASE2","title":"Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2025-02-17","conditions":"Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia","enrollment":200},{"nctId":"NCT05554133","phase":"NA","title":"Precision Optical Guidance for Oral Biopsy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-15","conditions":"Oral Lesions","enrollment":90},{"nctId":"NCT01269190","phase":"NA","title":"Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-12-30","conditions":"Oral Cavity Neoplasm","enrollment":275},{"nctId":"NCT07260344","phase":"NA","title":"Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral Precancer","status":"NOT_YET_RECRUITING","sponsor":"Anil Chaturvedi","startDate":"2025-12-15","conditions":"Oral Precancer, Oral Cancer, Oral Cancer Screening","enrollment":400},{"nctId":"NCT02790853","phase":"EARLY_PHASE1","title":"Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-25","conditions":"Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder","enrollment":63},{"nctId":"NCT04563754","phase":"PHASE1, PHASE2","title":"The Effectiveness of High Resolution Microendoscopy for People Living With HIV","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-07-30","conditions":"Anal High Grade Squamous Intraepithelial Lesion","enrollment":163},{"nctId":"NCT02714439","phase":"EARLY_PHASE1","title":"Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2016-10-25","conditions":"Malignant Neoplasms of Female Genital Organs","enrollment":157},{"nctId":"NCT02206048","phase":"NA","title":"Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-10-02","conditions":"Cervix Carcinoma","enrollment":9},{"nctId":"NCT05396781","phase":"PHASE2","title":"Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening","status":"COMPLETED","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2022-01-13","conditions":"Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia","enrollment":41},{"nctId":"NCT02335372","phase":"NA","title":"Cervical Cancer Screening Study in Brazil","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-06","conditions":"Cervical Cancer","enrollment":300},{"nctId":"NCT02420665","phase":"EARLY_PHASE1","title":"Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Cervical Cancer","enrollment":50},{"nctId":"NCT02018367","phase":"PHASE2","title":"Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma","status":"UNKNOWN","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2012-09","conditions":"Barrett's Esophagus","enrollment":100},{"nctId":"NCT02029937","phase":"PHASE2","title":"High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia","status":"UNKNOWN","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2014-01","conditions":"Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia","enrollment":1300},{"nctId":"NCT01456143","phase":"NA","title":"Optical Imaging of Head and Neck Cancer","status":"TERMINATED","sponsor":"Sharmila Anandasabapathy, MD","startDate":"2011-12","conditions":"Squamous Cell Carcinoma, Neoplasia, Head and Neck Cancer","enrollment":33},{"nctId":"NCT02207959","phase":"PHASE1","title":"Gastric In Vivo Study","status":"TERMINATED","sponsor":"Susana Gonzalez","startDate":"2015-01","conditions":"Gastric Cancer","enrollment":8},{"nctId":"NCT02494310","phase":"NA","title":"HRME: Screening for Cervical Cancer and Its Precursors in Low-Resource Settings","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2015-09-01","conditions":"Neoplasia of the Uterine Cervix, Cancer Prevention, Cervical Intraepithelial Neoplasia","enrollment":200},{"nctId":"NCT01384227","phase":"EARLY_PHASE1","title":"Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study","status":"COMPLETED","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2009-02","conditions":"Barrett's Esophagus","enrollment":40},{"nctId":"NCT01384695","phase":"EARLY_PHASE1","title":"A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1","status":"TERMINATED","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2009-06","conditions":"GERD, Barrett's Esophagus","enrollment":67},{"nctId":"NCT01384240","phase":"EARLY_PHASE1","title":"Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia","status":"TERMINATED","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2010-04","conditions":"Colon Polyps, Colonic Dysplasia, Anal Dysplasia","enrollment":183},{"nctId":"NCT01384708","phase":"EARLY_PHASE1","title":"Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer","status":"COMPLETED","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2010-08","conditions":"Squamous Cell Cancer","enrollment":70},{"nctId":"NCT01384864","phase":"EARLY_PHASE1","title":"Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia","status":"COMPLETED","sponsor":"Anandasabapathy, Sharmila, M.D.","startDate":"2011-08","conditions":"Barrett's Esophagus, Intraepithelial Neoplasia","enrollment":30},{"nctId":"NCT02095847","phase":"PHASE2","title":"High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"","conditions":"Uterine Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Proflavine"],"phase":"marketed","status":"active","brandName":"Proflavine Hemisulfate","genericName":"Proflavine Hemisulfate","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Proflavine hemisulfate is an acridine dye that intercalates into DNA and generates reactive oxygen species, causing direct antimicrobial and antiproliferative effects. Used for Topical antiseptic and antimicrobial agent (historical use), Investigational anticancer agent (limited clinical development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}